Cardiac-specific overexpression of HIF-1α prevents deterioration of glycolytic pathway and cardiac remodeling in streptozotocin-induced diabetic mice

American Journal of Pathology

Volumn 177, Issue 1, 2010, Pages 97-105

  Xue, Wanli ^a,b,c   Cai, Lu ^a,b   Tan, Yi ^a,b   Thistlethwaite, Patricia ^d   Kang, Y James ^a   Li, Xiaokun ^b   Feng, Wenke ^a,b  

^a University of Louisville School of Medicine   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENIC FACTOR; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLYCOLYTIC ENZYME; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN; STREPTOZOCIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME ASSAY; GENE OVEREXPRESSION; GENE TARGETING; GLYCOLYSIS; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART PROTECTION; HISTOPATHOLOGIC SKIN REACTION; MALE; MOUSE; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

EID: 77954608736     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091091     Document Type: Article

References (44)

1. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL: Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002, 105:373-379
2. Rodrigues B, Cam MC, McNeill JH: Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998, 180:53-57
3. Ye G, Donthi RV, Metreveli NS, Epstein PN: Overexpression of hexokinase protects hypoxic and diabetic cardiomyocytes by increasing ATP generation. Cardiovasc Toxicol 2005, 5:293-300
4. Yoon Ys, Uchida S, Masuo O, Cejna M, Park JS, Gwon Hc, Kirchmair R, Bahlman F, Walter D, Curry C, Hanley A, Isner JM, Losordo DW: Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005, 111:2073-2085
5. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM: Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999, 154:355-363 (Pubitemid 29094086)
6. Carmeliet P: VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000, 6:1102-1103
7. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996, 271:32529-32537
8. Semenza GL, Shimoda LA, Prabhakar NR: Regulation of gene expression by HIF-1. Novartis Found Symp 2006, 272:2-8
9. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999, 59:3915-3918
10. Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ: Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 1995, 268:C1362-C1368
11. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E: Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 2001, 276:43836-43841
12. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L: Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 2004, 53:3226-3232 (Pubitemid 39564499)
13. Gao W, Ferguson G, Connell P, Walshe T, Murphy R, Birney YA, O'Brien C, Cahill PA: High glucose concentrations alter hypoxia-induced control of vascular smooth muscle cell growth via a HIF-1[alpha]-dependent pathway. J Mol Cell Cardiol 2007, 42:609-619 (Pubitemid 46349124)
14. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, Gurtner GC: Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 2008, 283:10930-10938
15. Feng W, Wang Y, Cai L, Kang YJ: Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions. Biochem Biophys Res Commun 2007, 360:286-289 (Pubitemid 46990356)
16. Chen JX, Stinnett A: Ang-1 gene herapy inhibits hypoxia-inducible factor-1{alpha} (HIF-1{alpha})-prolyl-4-hydroxylase-2, stabilizes HIF-1{alpha} expression, and normalizes immature vasculature in db/db mice. Diabetes 2008, 57:3335-3343
17. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA: Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol 2005, 46:2116-2124
18. Cai L, Wang J, Li Y, Sun X, Wang L, Zhou Z, Kang YJ: Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 2005, 54:1829-1837
19. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L: Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006, 113:544-554
20. Wang Y, Feng W, Xue W, Tan Y, Hein DW, Li XK, Cai L: Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 2009, 58:1391-1402
21. Xue W, Liu Q, Cai L, Wang Z, Feng W: Stable overexpression of human metallothionein-IIA in a heart-derived cell line confers oxidative protection. Toxicol Lett 2009, 188:70-76
22. England K, O'Driscoll C, Cotter TG: Carbonylation of glycolytic proteins is a key response to drug-induced oxidative stress and apoptosis. Cell Death Differ 2004, 11:252-260
23. Wang Q, Donthi RV, Wang J, Lange AJ, Watson LJ, Jones SP, Epstein PN: Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia. Am J Physiol Heart Circ Physiol 2008, 294:H2889-H2897
24. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408
25. Feng W, Ye F, Xue W, Zhou Z, Kang YJ: Copper regulation of hypoxia-inducible factor-1 activity. Mol Pharmacol 2009, 75:174-182
26. Feng W, Cai J, Pierce WM, Franklin RB, Maret W, Benz FW, Kang YJ: Metallothionein transfers zinc to mitochondrial aconitase through a direct interaction in mouse hearts. Biochem Biophys Res Commun 2005, 332:853-858
27. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001, 15:1406-1418
28. Agani F, Semenza GL: Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity. Mol Pharmacol 1998, 54:749-754
29. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL: Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha. Genes Dev 1998, 12:149-162
30. Ryan HE, Lo J, Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998, 17:3005-3015
31. Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, Johnson RS, Giordano FJ: Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J 2004, 18:1138-1140
32. Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, Davies PJ, Taegtmeyer H: Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 2000, 32:985-996
33. Stanley WC, Lopaschuk GD, McCormack JG: Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997, 34:25-33
34. Rodrigues B, McNeill JH: The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992, 26:913-922
35. Semenza GL: Perspectives on oxygen sensing. Cell 1999, 98:281-284
36. Braithwaite SS, Palazuk B, Colca JR, Edwards CW III, Hofmann C: Reduced expression of hexokinase II in insulin-resistant diabetes. Diabetes 1995, 44:43-48
37. Belke DD, Larsen TS, Gibbs EM, Severson DL: Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000, 279:E1104-E1113
38. Noda C, Masuda T, Sato K, Ikeda K, Shimohama T, Matsuyama N, Izumi T: Vanadate improves cardiac function and myocardial energy metabolism in diabetic rat hearts. Jpn Heart J 2003, 44:745-757
39. Ye G, Metreveli NS, Ren J, Epstein PN: Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003, 52:777-783
40. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, Epstein PN: Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004, 53:1336-1343
41. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K: Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115:2108-2118
42. Taniyama Y, Ito M, Sato K, Kuester C, Veit K, Tremp G, Liao R, Colucci WS, Ivashchenko Y, Walsh K, Shiojima I: Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. J Mol Cell Cardiol 2005, 38:375-385
43. Jiang Y, Reynolds C, Xiao C, Feng W, Zhou Z, Rodriguez W, Tyagi SC, Eaton JW, Saari JT, Kang YJ: Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med 2007, 204:657-666
44. Zhou Y, Jiang Y, Kang YJ: Copper reverses cardiomyocyte hypertrophy through vascular endothelial growth factor-mediated reduction in the cell size. J Mol Cell Cardiol 2008, 45:106-117